Published in Pharma Investments, Ventures and Law Weekly, December 18th, 2005
Under the terms of the agreement, Open Biosystems gains exclusive rights to develop and commercialize products based on Tranzyme's technology. In addition, the company will assume Tranzyme's operations located in Birmingham, Alabama, where Open Biosystems will continue to expand the development and production of lentiviral based products. In return, Tranzyme will receive minimum annual payments and royalties on sales of products and services resulting from the application of Tranzyme's technology....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly